Stock_Titan Posted - 4 hours ago

$ARGX argenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024 https://www.stocktitan.net/news/ARGX/argenx-to-report-first-quarter-2024-financial-results-and-business-iizcx202mmwq.html

WhisperNumber Posted - 04/23/24

$BIIB #earnings before open Wed, the expectation from the WhisperNumber community is $3.56, 12c ahead of analyst estimates. Earnings came in $0.35 short of the whisper last quarter. 61% beat rate. Implied movement +/-5.5%. https://www.whispernumber.com/wr_options_alerts.jsp #options $ARGX $BNTX

erevnon Posted - 04/18/24

Wedbush reiterates argenx $ARGX at Outperform and maintains a price target of https://marketsblock.com/stock-upgrades-and-downgrades/

doubledown5 Posted - 04/17/24

$ZLAB $ARGX had good news yesterday and this puppy still lags make it make sense, remaining optimistic as every investor is underwater now. Bios are so difficult

Stocksrunner Posted - 04/17/24

Warren Buffett's advice to be greedy when others are fearful applies to $ARGX $BLTE and $OLK Technical analysis shows these stocks are in oversold territory, which could present a buying opportunity for risk-tolerant investors.

JGNYC Posted - 04/16/24

$ARGX buying for PDUFA in June

DonCorleone77 Posted - 04/16/24

$ARGX Argenx presents data from ADHERE trial evaluating Vyvgart Hytrulo Argenx announced that data from its Phase 3 ADHERE trial evaluating Vyvgart Hytrulo in patients with chronic inflammatory demyelinating polyneuropathy, or CIDP, were presented for the first time to the medical community during the Clinical Trials Plenary Session at the American Academy of Neurology, or AAN, annual meeting in Denver, Colorado. Argenx also highlighted clinical trial and real-world data across seven posters and presentations that continue to reinforce Vyvgart and Vyvgart Hytrulo as a transformative treatment option for gMG patients. In the ADHERE study, a majority of patients treated with Vyvgart Hytrulo, regardless of prior treatment, demonstrated evidence of rapid clinical improvement, and a reduced risk of relapse compared to those treated with placebo. As previously reported, ADHERE met its primary endpoint demonstrating a 61% reduction in the risk of relapse versus placebo. Vyvgart Hytrulo was well-tolerated, and the observed safety and tolerability profile was consistent with previous clinical trials. Evidence of rapid onset and maintenance of clinical response: In the open-label Stage A of the ADHERE study, 67% of patients treated with Vyvgart Hytrulo demonstrated evidence of clinical improvement, or ECI, including 40% who had achieved ECI by the earliest possible measure at week 4. In Stage B, Vyvgart Hytrulo-treated patients maintained a clinical response to treatment longer than those on placebo as evidenced by a statistically significant and clinically relevant reduction in risk of relapse. Results across both Stage A and B indicate IgG autoantibodies play a significant role in mediating the underlying biology of CIDP. Overall, 81% of Vyvgart Hytrulo-treated patients demonstrated one point improvement on the aINCAT as compared to baseline Stage A scores in ADHERE, which includes 42% of patients with two-point improvement, 28% with three-point improvement, and 12% with four-point improvement. Clinical benefit was seen across all patient subtypes, including those who had previously received corticosteroids, intravenous or subcutaneous immunoglobulin, or were on no treatment prior to study entry. In total, 99% of eligible patients continued to the ADHERE-Plus open-label extension study. Data from the ADHERE trial were submitted to the FDA as part of a supplemental Biologics License Application, or sBLA, for VYVGART Hytrulo for the treatment of CIDP. The application was accepted for priority review in February and has been granted a PDUFA target action date of June 21.

Stock_Titan Posted - 04/16/24

$ARGX argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease https://www.stocktitan.net/news/ARGX/argenx-data-highlight-evidence-that-vyvgart-and-vyvgart-hytrulo-7vhzzro7jcy1.html

forprofit12 Posted - 04/09/24

$ARGX why so much weakness?

FonsieTrader Posted - 03/28/24

Revolutionizing Targeted Cancer Treatment and Radiotherapy Manufacturing: Actinium Pharmaceuticals (NYSE: ATNM) Trailblazing Journey $ARGX $ATNM $MRNA https://www.benzinga.com/pressreleases/24/03/ab37977023/revolutionizing-targeted-cancer-treatment-and-radiotherapy-manufacturing-actinium-pharmaceuticals via @Benzinga

Quantumup Posted - 03/27/24

Oppenheimer🏁 $IMVT Outperform/$50~sees $IMVT ($5B Mcap) shifting the balance of power from $ARGX ($24B Mcap) as its anti-FcRn antibody candidates advance toward the mkt; believes batoclimab dosing flexibility/admin simplicity offer favorable differentiation vs Vyvgart. Sees IMVT-1402 =pot BiC.

erevnon Posted - 03/27/24

HC Wainwright & Co. maintains argenx $ARGX at Buy and maintains a price target of https://marketsblock.com/stock-upgrades-and-downgrades/

Stock_Titan Posted - 03/27/24

$ARGX argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease https://www.stocktitan.net/news/ARGX/argenx-advances-clinical-development-of-efgartigimod-in-primary-e5en6ahmsgu7.html

Stock_Titan Posted - 03/26/24

$ARGX argenx Announces Annual General Meeting of Shareholders on May 7, 2024 https://www.stocktitan.net/news/ARGX/argenx-announces-annual-general-meeting-of-shareholders-on-may-7-xgr3lom7tkxf.html

erevnon Posted - 03/26/24

Scotiabank maintains argenx $ARGX at Sector Perform and raises the price target from $402 to https://marketsblock.com/stock-upgrades-and-downgrades/

Stock_Titan Posted - 03/26/24

$ARGX argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia https://www.stocktitan.net/news/ARGX/argenx-announces-approval-of-vyvgart-efgartigimod-alfa-in-japan-for-lc6ox2xzdohb.html

Thestocktraderhubzee Posted - 03/22/24

$ARGX JMP Securities Reiterates Market Outperform on argenx, Maintains $471 Price Target

Borgati Posted - 03/22/24

$ARGX no competition for years to come. See you at $500

DEXWireNews Posted - 03/21/24

$ARGX https://www.tradingview.com/chart/ARGX/2wV0sOXj-Argenx-Lead-as-Chugai-s-Muscle-Disease-Treatment-Disappoints/2wV0sOXj

JGNYC Posted - 03/21/24

$ARGX $450's June calls gonna print af.. average down was taking a beatdown

Jonita Posted - 03/21/24

$ARGX 💣💣💣💣😂

InItToWinIt100 Posted - 03/21/24

Watch list 3/21/24 $ARGX $TRML $MU $AVGO $FIVE

OpenOutcrier Posted - 03/21/24

$ARGX (+12.1% pre) Roche falls, Argenx (ARGX) gains after Chugai's Ensprayng drug for myasthenia gravis fails - SI https://ooc.bz/l/28308

DonCorleone77 Posted - 03/21/24

$ARGX $RHHBY Argenx rallies after Chugai generalized myasthenia gravis study fails Shares of Argenx (ARGX) after rising after Roche's (RHHBY) Chugai Pharmaceutical announced results from its Phase III LUMINESCE study of Enspryng, an investigational treatment for generalized myasthenia gravis. Statistically significant data was observed in its primary endpoint, however the results did not reach expectations on the degree of clinical benefit, the company in a statement. Shares of Argenx, which markets Vyvgart for generalized myasthenia gravis, are up 12% in premarket trading.

theflynews Posted - 03/21/24

Argenx rallies after Chugai generalized myasthenia gravis study fails - $ARGX - https://thefly.com/permalinks/entry.php/ARGXid3885678

bernardbaruch Posted - 03/21/24

@tradingtwenty $argx is a $20 B plus mkt cap fwiw

Funtoers Posted - 03/14/24

@tradingtwenty $ARGX market cap isn’t 2,09 M, it’s way bigger.

tradingtwenty Posted - 03/14/24

Top 5 stocks by smallest market cap that have trended in the past 24 hours: $ARGX 2.09M 🔥 $TNON 2.77M $BPTH 3.67M $HSDT 5.17M $IFBD 7.9M Link: https://tradingtwenty.com/dashboard/trending/past

kaefer Posted - 03/13/24

$ARGX $AVTX $BPTH $LSF $TNON

Quantumup Posted - 03/13/24

Goldman Sachs initiated🏁 $IMVT Buy/$50~sees pot for IMVT-1402 to emerge as a BiC anti-FcRn antibody given its ability to elicit deep IgG reductions, subcutaneous formulation, and safety profile; ascribes $4.4B peak sales potential, w/ upside pot of $6.2B — pending best-in-class efficacy. $roiv $argx